Up 68% but still yielding 7.1%, I've been loading up on Aberdeen shares
Improving numbers
The asset manager is due to report H1 results next week. Should the positive momentum seen in Q1 continue, then we could be on the cusp of a major recovery in its share price.
Last quarter, its direct-to-consumer offering, interactive investor (ii) continued its strong growth momentum. Total customer numbers were up to 450,000. This included 88,000 high-value SIPP accounts.
ii has been very successful in tapping into a growing trend – the increasing importance of private investors to markets. With the spread of online investment forums, YouTube, and the like, individual investors have more power to move markets than at any time in history.
Last quarter, during the tariff-induced selloff, ii saw record levels of engagement with an average of 24,000 trades per day on the platform. In the first half of April, it saw four of its highest trading days ever, as private investors swooped to buy stocks on the cheap.
Fund outflows
For all the success of ii, the reality is that a sustained recovery in Aberdeen's share price will only occur if it can get a grip on falling assets under management.
Over the last few years, its Adviser business has simply haemorrhaged funds. The business is working hard to regain the trust of independent financial advisers, who recommend funds for their clients to buy.
In Q1, Adviser saw outflows of £600m. This was its 'best' performance over the past six quarters. A couple of years back, outflows were in the billions.
By 2026, it's aiming for greater than 70% of its total funds to beat a benchmark index. I certainly expect it to achieve that with its bond funds, which regularly hit over 90%. But I'm less confident that equity-only funds will achieve that milestone.
It's not just Aberdeen equity funds that struggle to beat a benchmark; this is an industry-wide problem. Over the last few years, unless a fund manager was invested in the Magnificent 7 stocks, it had zero chance of beating the S&P 500, the most tracked index.
Structural trends
If it can get its Adviser business back to profitability, then the opportunity is massive. Despite recent blunders, like the ill-fated 'abrdn' fiasco, I still view the asset manager as one of the most respected in the industry.
The UK wealth industry is growing. Over the next 25 years, over £5.5trn of wealth will be passed on by the baby boomers. In the more immediate future, over the next three years, the number of people retiring annually is estimated to be about 750,000.
Now more than ever people are beginning to wake up to the fact that the State Pension will no longer fund the kind of retirement they want. With deep expertise in long-term financial planning, Aberdeen looks well placed to provide innovative retirement solutions.
Over the last few months, I have been loading up on the stock at every available opportunity. I think my future self will thank me.
The post Up 68% but still yielding 7.1%, I've been loading up on Aberdeen shares appeared first on The Motley Fool UK.
More reading
5 Stocks For Trying To Build Wealth After 50
One Top Growth Stock from the Motley Fool
Andrew Mackie owns shares in Aberdeen. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.
Motley Fool UK 2025
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 hours ago
- Yahoo
3 Reasons Why Coca-Cola Is Still a Top Dividend Stock for Generating Passive Income
Key Points Coke continues to generate organic growth despite a highly challenging operating environment. The company is adapting to changing consumer preferences and regulatory pressure by offering Coke made with U.S. cane sugar instead of corn syrup. Coke has a growing and affordable dividend with a competitive yield. 10 stocks we like better than Coca-Cola › Some top stocks are known for their growth potential, while others are recognized for their predictability. Coca-Cola (NYSE: KO) is in that second camp. The company isn't perfect, and its results have been disappointing in some periods. But through it all, one constant that investors have been able to count on is Coke's rock-solid dividend. Coke is unique because it has a high yield at 3% and it has an extensive track record of increasing its payout. It has done so for 63 consecutive years, earning it a spot on the list of Dividend Kings. Here's why Coke remains a great buy for investors looking to boost their passive income. 1. Delivering solid results Coke reported a good second quarter on July 22. The company grew organic revenue by 5%, comparable earnings per share (EPS) by 4%, and comparable operating margins rose to 34.7% versus 32.8% for the second quarter of 2024. For the full year, Coke expects organic revenue growth of 5% to 6%, comparable currency-neutral EPS of 8%, and comparable EPS of $2.88. So currency headwinds are really throwing a wrench in Coke's results and detracting from the strength of the underlying business. Coke's resilient results didn't get a big reaction from Wall Street, but that may be because Coke is up around 11% on the year, which is slightly better than the gain for the S&P 500 (SNPINDEX: ^GSPC). Coke has been a standout in what has otherwise been a challenging consumer staples sector -- especially for packaged food and beverage and snack companies. Many food and beverage stocks are at multiyear, if not multidecade, lows. Inflation and relatively high interest rates have been hitting consumer demand hard for everyday household goods. When the cost of these goods go up, it affects all consumers, but especially those with less discretionary income. Another challenge is changes in consumer preferences. Some consumers are shifting their buying behavior toward healthier options, characterized by lower sugar content, better ingredients, and improved nutrition. These trends were reflected in Coke's latest results, which highlighted volume growth in Coca-Cola Zero Sugar, Diet Coke, Fanta, Fairlife, BodyArmor, and Powerade. For years now, Coke has been seeing excellent growth in zero sugar and diet versions of its flagship Coca-Cola products -- a sign that investment in these labels is paying off. 2. Adapting to the times The Trump administration's Make America Healthy Again Commission is pressuring food and beverage companies to phase out petroleum-based synthetic dyes and replace artificial ingredients with natural ingredients. On its latest earnings call, Coke said that it plans to expand its Trademark Coca-Cola product range to include U.S. cane sugar this fall. In the U.S., Coke uses high-fructose corn syrup as its primary sweetener because it is cost-effective. But Coke made in Mexico typically uses cane sugar, which is why some consumers tend to go out of their way to buy this product version. The decision to make Coke with cane sugar in the U.S. may have garnered a negative reaction if announced years ago, but the time is right to make this change. Coke's standout brands in recent years have generally been the healthier options in its portfolio. It has had resounding success growing Topo Chico since it acquired the brand in 2017. Similarly, its dairy brand Fairlife (acquired in 2020) has been a value add for the company. Not only are these brands doing well, but they also diversify Coke away from a majority soda lineup toward other options, which makes the company better positioned to unlock earnings growth from a diversified revenue stream. 3. A growing and affordable dividend Money isn't created out of thin air. For a company to consistently grow its dividend and thus incur a larger dividend expense, it must grow its earnings. Coke's earnings growth hasn't been great in recent years, but that's mostly because it has been making significant changes to its brand lineup and addressing the aforementioned challenges. However, the growth has been sufficient for Coke to continue increasing its dividend. Coca-Cola pays a $0.51 per share quarterly dividend, or $2.04 per year. If Coke hits its adjusted EPS guidance of 3%, earnings will be $2.97 in 2025 -- meaning that Coke can afford to grow its dividend without impacting its financial health or taking away cash that could otherwise be reinvested in the business. Coke also has a reasonable valuation. Based on the share price of $69.17 at the time of this writing and $2.97 in 2025 earnings, Coke would have a price-to-earnings ratio of 23.3. It's not a bargain-bin price for a low-growth dividend stock. And there are plenty of better deals available for investors seeking a superior value. However, Coke arguably deserves this valuation because the dividend is so reliable, and the company continues to generate organic growth and pricing power at a time when many of its peers are struggling. A potential centerpiece of a passive income portfolio Coke's brand lineup, high-margin business, and willingness to adapt to changes in consumer preferences make the company a worthy foundational holding for income investors. The shift from corn syrup to cane sugar in the U.S. may lead to higher costs in the near term, but the move could pay off if it increases sales volumes. Coke continues to demonstrate why it is the industry leader across numerous non-alcoholic beverage categories, and why the stock remains a plug-and-play option for income investors to add to their portfolios. Do the experts think Coca-Cola is a buy right now? The Motley Fool's expert analyst team, drawing on years of investing experience and deep analysis of thousands of stocks, leverages our proprietary Moneyball AI investing database to uncover top opportunities. They've just revealed their to buy now — did Coca-Cola make the list? When our Stock Advisor analyst team has a stock recommendation, it can pay to listen. After all, Stock Advisor's total average return is up 1,041% vs. just 183% for the S&P — that is beating the market by 858.71%!* Imagine if you were a Stock Advisor member when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $636,628!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,063,471!* The 10 stocks that made the cut could produce monster returns in the coming years. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of July 28, 2025 Daniel Foelber has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. 3 Reasons Why Coca-Cola Is Still a Top Dividend Stock for Generating Passive Income was originally published by The Motley Fool Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Maziar Mike Doustdar appointed as president and chief executive officer of Novo Nordisk
Bagsværd, Denmark, 29 July 2025 – Novo Nordisk today announced that Maziar Mike Doustdar has been appointed as president and chief executive officer, effective 7 August 2025. Mike Doustdar succeeds Lars Fruergaard Jørgensen, who will step down as president and chief executive officer on the same date. The company also announced other executive-level changes, effective 7 August. Mike Doustdar, currently Novo Nordisk's executive vice president of International Operations, has a strong track record of creating value and driving growth. Under his leadership over the past decade, Novo Nordisk's International Operations have more than doubled sales to approximately DKK 112 billion in 2024. The business includes all of Novo Nordisk's affiliates outside of the US and employs nearly 20,000 people. Novo Nordisk Chair, Helge Lund, said: 'Mike is an exceptional leader and has the unanimous support of the Board. We are confident that he is the best person to lead Novo Nordisk through its next growth phase. Mike has consistently demonstrated the ability to drive growth through strong commercial execution and building high-performing teams. This is an important moment for Novo Nordisk. The market is developing rapidly, and the company needs to address recent market challenges with speed and ambition. I believe Novo Nordisk will build on its strengths as a global leader in obesity and diabetes, and Mike has a clear vision of how to unlock the full potential of the opportunities ahead.' Mike Doustdar has been appointed as the result of a comprehensive process that included external and internal candidates. The Novo Nordisk Foundation fully endorses Novo Nordisk Board's decision to appoint Maziar Mike Doustdar as president and chief executive officer. Mike Doustdar said: 'It's an enormous privilege to lead this company at a time of tremendous opportunity and change. I come to this role with a sense of urgency, a laser focus on high performance, and a fierce determination for Novo Nordisk to aim higher than it's ever done, and to deliver to many more patients the innovation they need. From my decades in leadership roles across Novo Nordisk, I know the extraordinary talent and commitment of our people and the excellence of our science. This has enabled us to achieve great things in the past and will ensure we continue to do so in the future.' Novo Nordisk Chair, Helge Lund, added: 'Under Lars's leadership, Novo Nordisk has undergone a profound period of growth and now reaches millions more patients with life-changing medicines. On behalf of Novo Nordisk's Board of Directors and our employees, I want to thank Lars for 34 years of unstinting commitment to the company and wish him all the best in his future endeavours.' Other organisational changes effective 7 August: Research & Early Development and Development EVP areas will be merged into a combined R&D Nordisk has decided to merge the company's Research & Early Development with its Development area into a new, consolidated R&D unit, under the leadership of Martin Holst Lange, MD, PhD. Martin Holst Lange, currently executive vice president, Development, will be appointed chief scientific officer (CSO), effective 7 August. Martin Holst Lange will focus on seamlessly combining the two functions, quickly advancing the innovation of new therapies and ensuring the success of the early and late-stage pipelines, with a significant focus on the diabetes and obesity areas. In addition, Martin Holst Lange will work closely with Mike Doustdar to drive pipeline development and innovation from both within and outside of the company. Marcus Schindler, executive vice president, Research & Early Development and CSO, has decided to retire from the company. Novo Nordisk Chair, Helge Lund, said: 'We thank Marcus for his deep commitment to Novo Nordisk and its pursuit of scientific excellence. We wish him all the best for the future.' Marcus Schindler joined Novo Nordisk in January 2018 as senior vice president of External Innovation and Strategy and has been CSO since 2021. Marcus Schindler has played an integral role in leading the discovery of early scientific innovation. He will remain at Novo Nordisk for a short period to ensure a successful transition. Emil Kongshøj Larsen, currently senior vice president of the Europe and Canada region (EUCAN), will join Executive Management and succeed Mike Doustdar, assuming the responsibility of executive vice president, International Operations. Emil Larsen currently leads a region spanning 40 countries, accounting for about 20% of Novo Nordisk's global sales. He has previously led other significant business areas throughout Europe, Africa and the Middle East, as well as Commercial Affairs and Strategy in International Operations. With these changes, Executive Management will have the following members, effective 7 August: Maziar Mike Doustdar, president and CEO* Thilde Hummel Bøgebjerg, EVP, Quality, IT & Environmental Affairs Emil Kongshøj Larsen, EVP, International Operations Ludovic Helfgott, EVP, Product & Portfolio Strategy Karsten Munk Knudsen, EVP, chief financial officer* Martin Holst Lange, EVP, chief scientific officer, Research & Development David Moore, EVP, US Operations Tania Sabroe, EVP, People, Organisation and Corporate Affairs Henrik Wulff, EVP, CMC & Product Supply * Registered as an executive with the Danish Business Authority. About Maziar Mike DoustdarMike Doustdar became senior vice president of International Operations in 2013, a business that includes 80 affiliates - all of Novo Nordisk's commercial affiliates outside of the US. Novo Nordisk's International Operations had sales of approximately DKK 112 billion in 2024 and serve approximately 35 million patients. Prior to this role, Mike led Novo Nordisk's Southeast Asia and Oceania commercial area out of Malaysia, following on from his leadership of the Middle East business. Prior to this, he was general manager based in Turkey and held leadership roles in finance and IT. Mike Doustdar became executive vice president in 2015. He is a member of the Board of Directors of Orion Corporation. Conference CallNovo Nordisk will host a conference call for investors at 14.30 CEST on 29 July 2025, corresponding to 8.30 am EST. For more information on how to listen, please visit the investor section of There will be a conference call for media at 16.00 CEST, which corresponds to 10.00 am EST. Novo Nordisk is a leading global healthcare company founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat serious chronic diseases built upon our heritage in diabetes. We do so by pioneering scientific breakthroughs, expanding access to our medicines and working to prevent and ultimately cure disease. Novo Nordisk employs about 77,400 people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B). Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit Facebook, Instagram, X, LinkedIn and YouTube. Contacts for further information Media: Ambre James-Brown +45 3079 9289abmo@ Liz Skrbkova (US)+1 609 917 0632lzsk@ Investors: Jacob Martin Wiborg Rode+45 3075 5956jrde@ Sina Meyer +45 3079 6656azey@ Max Ung+45 3077 6414 mxun@ Frederik Taylor Pitter +1 609 613 0568fptr@ Publication of inside information pursuant to Market Abuse Regulation, Article 17 Company announcement No 19 / 2025 Attachment CA250729-CEO-succession
Yahoo
3 hours ago
- Yahoo
Food delivery service Calo scores $39 million in Series B extension as it sets eyes on the UK
Middle Eastern food delivery startup Calo said Tuesday it has raised $39 million in a Series B extension that was led by AlJazira Capital. The fundraise, which was more than 1.5x of its original $25 million raise in December, also saw participation from existing backers such as Nuwa Capital, STV, Khwarizmi Ventures, and Al Faisaliah Group. The company is using this funding to expand into territories like the UK and also explore different partnerships in physical space. Calo primarily offers ready-to-eat meals that customers can heat up later. The company delivers different plans to cater to various health goals. The company's founder, Ahmed Al Rawi, told TechCrunch the startup's revenue grew by 'close to 100%.' Calo delivered more than 10 million meals last year in Saudi Arabia, the UAE, Kuwait, Qatar, and Bahrain. While Al Rawi didn't provide a number for this year, he said the deliveries were growing in step with revenue. Those numbers, along with its brand, technology, and operational excellence, convinced AlJazira Capital to invest in the Saudi company. 'Calo represents a compelling opportunity at the intersection of healthtech, foodtech, and consumer subscription models,' Rawan AlRasheed, director of venture capital at AlJazira Capital told TechCrunch in a statement. The startup is also making moves to expand in the UK, where last year it acquired two meal delivery services, Fresh Fitness Food and Detox Kitchen. While Fresh Fitness Food didn't raise any money, Detox Kitchen had raised just over $3.4 million via a mix of venture-backed and equity crowdfunding rounds, according to Crunchbase data. 'We spoke to over 50 meal subscription businesses worldwide, ranging from the U.S. to Asia, in 2023-24 to learn about what is an exciting market for us to expand to. We realized the UK was the right market for us to expand. We thought that both companies that we acquired had a great culture fit to work with Calo,' Al Rawi told TechCrunch over a call. He added that Calo acquired these businesses because they had their operational layer figured out, and the startup just wanted to upscale the tech and branding layer. Al Rawi said Calo spent most of this year integrating its technology and process with both UK platforms without laying off any of the existing personnel. The startup finished the integration work in July and has been slowly making a marketing push in the UK. Calo can currently deliver meals in London daily and in other parts of the UK two to three times a week. The founder said that Calo is targeting to get to 10x its revenue in the UK in the next three years. Those UK ambitions will be met with competition. Apart from traditional food delivery giants like Just Eat and Deliveroo, Calo will also compete with meal-box services such as Gusto and Wicked Kitchen. While Calo is focused on growing in the UK, the company is also looking to acquire different meal-kit services across the world. The company is also expanding physical locations, including retail stores and kiosks in other regions. The company has also partnered with a gym chain called Armah Sports Company in Saudi Arabia to offer a bundle of Calo and gym subscription. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
